Moreover, in a xenograft mammary 4T1 tumor model, it has been demonstrated that the concurrent administration of BAPN and the enzyme-responsive drug (NQO1-SN38), designed to target breast tumors with the topoisomerase I inhibitor SN38, results in a cooperative reduction in tumor growth [100]. This evidence concerns the gene NQO1 and neoplasm.